ClinicalTrials.gg

Program

HRS-5965

A development code. Also written as “HRS-5965 Capsules”, “HRS-5965 capsule” and “HRS-5965 tablets”.

In Jiangsu HengRui Medicine's pipeline, Factor B. Its studies are mostly in Glomerulonephritis, IGA · Hemoglobinuria, Paroxysmal · Anemia, Hemolytic · Glomerulonephritis, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Sep 10, 202414 company-led studies, 3 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine143 open or runningphase 3since Sep 10, 2024Aug 16, 2022Oct 2027phase 3 · NCT07014826
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-5965, phase 4, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2022First study: phase 1 study in GlomerulonephritisFirst studyNCT05505955 · 83 enrolled · China
  2. Sep 5, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT06051357 · 26 enrolled · China
  3. Nov 14, 2023Phase 2 study in Glomerulonephritis, IGANCT06137768 · 123 enrolled · China
  4. Jan 22, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06238544 · 132 enrolled · China
  5. Jun 23, 2024Phase 1 study in Paroxysmal Nocturnal Hemoglobinuria,IgA NephropathyNCT06490991 · 16 enrolled · China
  6. Aug 20, 2024Phase 1 study in Complement Mediated Primary or Secondary Glomerular DiseasesNCT06567392 · 6 enrolled · China
  7. Sep 10, 2024Phase 3 study in Hemoglobinuria, ParoxysmalNCT06593938 · 76 enrolled · China
  8. Nov 1, 20242 phase 1 studiesNCT06684041, NCT06674915
  9. Nov 28, 2024Phase 3 study in Hemoglobinuria, ParoxysmalNCT06715943 · 39 enrolled · China
  10. May 22, 2025Phase 3 study in Glomerulonephritis, IGANCT07014826 · 378 planned · China
  11. Jun 16, 20252 phase 1 studiesNCT07035665, NCT07040787
  12. May 6, 2026Phase 2 study in Glomerulonephritis, IGANCT07582133 · 380 planned · China

Ahead

  1. Oct 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT07014826
  2. Dec 2027Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06238544
  3. Jul 2029Primary completion: phase 2 study in Glomerulonephritis, IGANCT07582133

TargetBeta

“Factor B”the company's pipeline, read by Claude · source

Other programs on CFB

ProgramCompanyFurthest phaseStudies
iptacopanruleNovartisphase 325
NTQ5082ruleSino Biopharmaceuticalphase 36
FXS6837Fosun Pharmaphase 34
sefaxersenHoffmann-La Rochephase 31
HS-10542Hansoh Pharmaceutical Groupphase 23
FWY003Novartisphase 21
SAR446597Sanofiphase 21

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07582133Glomerulonephritis, IGA · China2RecruitingJul 2029380
NCT07040787Anemia, Hemolytic · China1CompletedAug 17, 202536
NCT07035665Glomerulonephritis, IGA · China1CompletedJul 22, 202516
NCT07014826Glomerulonephritis, IGA · China3RecruitingOct 2027378
NCT06715943Hemoglobinuria, Paroxysmal · China3CompletedJan 6, 202639
NCT06674915Complement Mediated Primary or Secondary Glomerular Diseases · China1CompletedJan 16, 202624
NCT06684041Anemia, Hemolytic · China1CompletedApr 7, 202532
NCT06593938Hemoglobinuria, Paroxysmal · China3CompletedJul 31, 202576
NCT06567392Complement Mediated Primary or Secondary Glomerular Diseases · China1CompletedOct 8, 20246
NCT06490991Paroxysmal Nocturnal Hemoglobinuria,IgA Nephropathy · China1CompletedAug 6, 202416
NCT06238544Hemoglobinuria, Paroxysmal · China2Active, not recruitingDec 2027132
NCT06137768Glomerulonephritis, IGA · China2CompletedOct 17, 2025123
NCT06051357Hemoglobinuria, Paroxysmal · China2CompletedMar 25, 202426
NCT05505955Glomerulonephritis · China1CompletedNov 3, 202383

How it is read

Names in the registry

  • “HRS-5965 Capsules”, 4 entries
  • “HRS-5965”, 3 entries
  • “HRS-5965 capsule”, 3 entries
  • “HRS-5965 tablets”, 2 entries
  • “HRS-5965 capsules”, 1 entry

Codes read as this program: HRS5965.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.